Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial

BACKGROUND: Despite the availability of effective vaccines against COVID-19, booster vaccinations are needed to maintain vaccine-induced protection against variant strains and breakthrough infections. This study aimed to investigate the efficacy, safety, and immunogenicity of the Ad26.COV2.S vaccine...

Descripción completa

Detalles Bibliográficos
Autores principales: Hardt, Karin, Vandebosch, An, Sadoff, Jerald, Le Gars, Mathieu, Truyers, Carla, Lowson, David, Van Dromme, Ilse, Vingerhoets, Johan, Kamphuis, Tobias, Scheper, Gert, Ruiz-Guiñazú, Javier, Faust, Saul N, Spinner, Christoph D, Schuitemaker, Hanneke, Van Hoof, Johan, Douoguih, Macaya, Struyf, Frank
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639796/
https://www.ncbi.nlm.nih.gov/pubmed/36113538
http://dx.doi.org/10.1016/S1473-3099(22)00506-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9639796/
https://www.ncbi.nlm.nih.gov/pubmed/36113538
http://dx.doi.org/10.1016/S1473-3099(22)00506-0

Ejemplares similares